An interventional study of STOPCOV in Covid19 and Sars-CoV-2 Infection, sponsored by Desmond Tutu HIV Foundation. Completed at 1 site in South Africa. Open to participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-09.
Sponsored by Desmond Tutu HIV Foundation · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 109 studies in COVID-19 with a site in South Africa — 7 open to participants now, 9 under way, 5 of them phase 3. COVID-19 · South Africa.
Among the 109 studies in COVID-19 with a site in South Africa, this one is the 58th largest by enrollment of the 95 interventional ones that give a count, is one of 38 that started in 2020, is one of 4 with no phase, and was the 72nd registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →7 of the 109 studies in COVID-19 with a site in South Africa are open now. Recruiting first, the newest first:
Douglas D. Fraser · Sites in South Africa, United States, Brazil and 4 more countries
Ages 18–65
Pfizer · Sites in South Africa, United States, Argentina and 16 more countries
Ages 12+
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in South Africa
Ages 18+
AstraZeneca · Sites in South Africa, United States, Argentina and 36 more countries
Ages 18+
Pfizer · Sites in South Africa, United States, Bulgaria and 4 more countries
Ages 0–17
A study can be open while its sites in South Africa have not opened yet or have stopped. Only those recruiting at a site in South Africa →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 12 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
109 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 50 · Phase 3 55
First in 2015; this study’s year is marked. 38 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 245 is above the median of 102 across 4,369 interventional studies indexed under COVID-19.
Median enrollment 384 across the 95 interventional studies, 833 across the 14 observational. Of the 94 that completed or were terminated, 49 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
67 of 109 have an industry lead sponsor. The 10 most frequent:
Desmond Tutu HIV Foundation is the lead sponsor of 6 studies on the registry; 3 are open to participants now.
Desmond Tutu HIV Foundation has 2 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
4 of the studies in COVID-19 with a site in South Africa that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT04746183University of LiverpoolAGILE (Early Phase Platform Trial for COVID-19) | 2027-03-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 109 studies in COVID-19 with a site in South Africa, from their registry updates:
This tab as a report to print or save as PDF → With an account.
South Africa recorded it's first coronavirus disease 2019 (COVID19) case on March 5, 2020. In response to the COVID19 outbreak World Health Organisation recommendations, South Africa implemented non-pharmaceutical recommendations. The major risk mitigation factors recommended by World Health Organisation and others - physical distancing and hygiene - are extremely difficult to implement in much of Africa. The investigators will conduct a randomised controlled trial to investigate the effect of an infection mitigation intervention to assess the effect on household transmission of severe acute respiratory syndrome (SARS) coronavirus (CoV) 2 in household settings with an index patient diagnosed SARS-CoV-2 positive.
The major risk mitigation factors recommended by World Health Organisation and others - physical distancing and hygiene - are extremely difficult to implement in much of Africa. Newly diagnosed SARS-CoV-2 index patients will be identified and recruited from a mobile clinic and local community clinics conducting SARS-CoV-2 testing. Index cases and their households will be invited to enroll. The study design is a type 2 hybrid cluster (household) randomised controlled trial, with outcomes assessed on index patients and their household contacts. 120 consecutively newly diagnosed index patients (GeneXpert severe acute respiratory syndrome coronavirus 2 PCR) and up to 6- 8 household contacts will be invited to participate in the trial as part of the prospective observational study evaluating transmission and symptoms. After completing consent, households will be randomised in a 1:1 ratio in blocks of 10 (60 households per group). Klipfontein is a resource-limited, densely populated, high HIV/tuberculosis disease burden areas in Cape Town. Newly diagnosed COVID19 cases will be identified from two sources: screening conducted in Desmond Tutu Health Foundation mobile screening units and local public sector clinics working closely with Desmond Tutu Health Foundation. Consecutive cases (n=120 cases and households) will be invited to participate in the randomised trial and prospective longitudinal follow up of up to 6- 8 household contacts. The contacts will be followed up after informed consent to SARS-CoV-2 screening, symptomatic questionnaires weekly up to 1 month. After enrolment, the household will be randomised to the infection mitigation intervention or enhanced usual care messaging. Baseline demographic, household characteristics questionnaire will be administered, and each household occupant invited to participate. Following consent procedures, household contacts (HHC) will be screened at baseline and weekly for 4 weeks for evidence of COVID19 infection. Specifically, the research team will conduct SARS-CoV-2 GeneXpert PCR testing and antibody serology. They will collate self- administered daily symptom checks on a weekly basis. The investigators will recruit 120 households over 1-11 months. The investigators will initiate a prospective longitudinal follow up of the household contacts of each case for 4 weeks in each case.
The investigators will calculate proportion of SARS-CoV-2 transmission from index cases in each household over 4- week period and describe the proportion of symptomatic and asymptomatic SARS-CoV-2 infection in a high density, low resourced community. Investigate the impact of the infection mitigation intervention by comparing incidence in households randomised to intervention versus standard of care. Secondary outcomes for the trial will include clinical outcomes (hospitalisations, death), linkages to care for people, psychosocial functioning, and stigma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
A fieldworker will deliver the STOPCOV pack and personal protective equipment at baseline. The fieldworker will communicate with intervention households daily, delivering STOPCOV hygiene information.
Other: STOPCOV
Participants received no additional messaging about managing COVID19 in the household.
Fieldworkers delivered an infection mitigation intervention which consisted of personal protective equipment and messaging on managing COVID19 and reducing onward transmission of SARS-CoV-2 infection.
SARS-CoV-2 Infection
Number of participants with positive SARS-CoV-2 PCR result
Time frame: 4 weeks
COVID19 Symptoms
Number of participants with SARS-CoV-2 serology antibody positive result
Time frame: 4 weeks
| Milestone | Stop Coronavirus (STOPCOV) | Control |
|---|---|---|
| Started | 137 | 108 |
| Completed | 137 | 108 |
| Not completed | 0 | 0 |
Number of participants with positive SARS-CoV-2 PCR result
| Participants | Stop Coronavirus (STOPCOV) | Control |
|---|---|---|
| SARS-CoV-2 Infection | 4 | 2 |
Number of participants with SARS-CoV-2 serology antibody positive result
| Participants | Stop Coronavirus (STOPCOV) | Control |
|---|---|---|
| COVID19 Symptoms | 11 | 9 |
Collected over 4 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Stop Coronavirus (STOPCOV) | 0/137 (0%) | 0/137 (0%) | 15/137 (10.9%) |
| Control | 0/108 (0%) | 0/108 (0%) | 4/108 (3.7%) |
| Event | Stop Coronavirus (STOPCOV) | Control |
|---|---|---|
| Pressure in chestRespiratory, thoracic and mediastinal disorders | 7/137 | 2/108 |
| Shortness of breathRespiratory, thoracic and mediastinal disorders | 6/137 | 1/108 |
| Somnolence/ drowsy/ sleepyRespiratory, thoracic and mediastinal disorders | 2/137 | 0/108 |
| Confused/ disorientedRespiratory, thoracic and mediastinal disorders | 0/137 | 1/108 |
| Age, Continuous(years) | Stop Coronavirus (STOPCOV) | Control | Total |
|---|---|---|---|
| Mean | 38.4 ± 16.6 | 39.9 ± 17.1 | 39.1 ± 16.8 |
| Sex: Female, Male(Participants) | Stop Coronavirus (STOPCOV) | Control | Total |
|---|---|---|---|
| Female | 79 | 60 | 139 |
| Male | 58 | 48 | 106 |
| Race/Ethnicity, Customized(Participants) | Stop Coronavirus (STOPCOV) | Control | Total |
|---|---|---|---|
| Race — Black | 69 | 22 | 91 |
| Race — Coloured | 68 | 82 | 150 |
| Race — Indian | 0 | 3 | 3 |
| Race — Prefer not to say | 0 | 1 | 1 |
| Region of Enrollment(participants) | Stop Coronavirus (STOPCOV) | Control | Total |
|---|---|---|---|
| South Africa | 137 | 108 | 245 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — There are no plans to share individual participant data with other researchers.
Ran from Sep 2020 to primary completion in Aug 2021, 10 months.
Results were first posted in Aug 2024, 3 years after primary completion.
Of 1,337 non-industry interventional studies with no phase under COVID-19, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 20. This study's 10 months is above that.
Counting every sponsor, half of 1,475 studies reached it within 9 months; a quarter within 3 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Desmond Tutu HIV Foundation